Skip to main content
. 2021 May 11;13(10):2290. doi: 10.3390/cancers13102290

Figure 4.

Figure 4

Prediction of the long-term efficacy based on the ratio of programmed death-ligand 1 (PD-L1)-positive circulating tumor cells (CTCs) at week 8. (a) Cutoff value of the PD-L1 positivity rates in the CTCs at week 8 to segregate the durable clinical benefits (DCB; n = 11) from the non-DCB (n = 5) calculated by the receiver operating characteristic (ROC) curve. (b) Kaplan–Meier curve for the progression-free survival (PFS). The PFS was significantly longer in patients with a ≥7.7% PD-L1 positivity rate (n = 8; median, 309.5 days) than that in patients with a < 7.7% PD-L1 positivity rate (n = 8; median, 172.5 days); ** p < 0.01. (c) Kaplan–Meier curve for the overall survival (OS). No significant difference in the OS between patients with ≥7.7% PD-L1 positivity rates (n = 8; median, 578 days) and in those with <7.7% PD-L1 positivity rates (n = 8; median, 906 days); p = 0.43.